AM

AM Resources Completes Compilation Work with the Discovery of 94 New Pegmatites for a Total of 281 Pegmatites on its 1,500 km² Land Package in Austria

Retrieved on: 
Thursday, April 18, 2024
Geology, News, AMR, QP, Plant, Suite (music), Government, Disclosure, Lithium

Compilation of government data resulted in the discovery of 94 additional pegmatites across two groups, with sizes ranging from 40 metres to 2,100 metres.

Key Points: 
  • Compilation of government data resulted in the discovery of 94 additional pegmatites across two groups, with sizes ranging from 40 metres to 2,100 metres.
  • Latest discoveries continue to reinforce AM Resources’ position in the Austrian Pegmatite Belt, located within proximity to European battery manufacturers.
  • AM Resources has now identified a total of 281 pegmatites, consolidating its strategic position in one of Austria’s most prospective lithium areas.
  • Mr. Lafleur is independent from the Company and has reviewed and approved the disclosure of the AM Resources geological information.

STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting

Retrieved on: 
Wednesday, April 17, 2024
Virtual, Cytosorbents Corporation, Randomized controlled trial, Cardiothoracic surgery, AATS, Professional corporation, KOL, European

PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal U.S. and Canadian Safe and Timely Antithrombotic Removal of Ticagrelor (STAR-T) randomized controlled trial will be featured as a late-breaking clinical trial presentation at the 104th Annual Meeting of the American Association for Thoracic Surgery (AATS), taking place Friday, April 26 through Tuesday, April 30, 2024 in Toronto, ON, Canada.

Key Points: 
  • PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal U.S. and Canadian Safe and Timely Antithrombotic Removal of Ticagrelor (STAR-T) randomized controlled trial will be featured as a late-breaking clinical trial presentation at the 104th Annual Meeting of the American Association for Thoracic Surgery (AATS), taking place Friday, April 26 through Tuesday, April 30, 2024 in Toronto, ON, Canada.
  • Details of the STAR-T presentation are as follows:
    Session presentation date & time: April 28, 2024 at 7:30-9:00 AM EDT
    Following the presentation at AATS, CytoSorbents will be hosting a Virtual KOL and Investor Day on Monday, May 6th at 11:30 AM to provide a review of the STAR-T pivotal trial results by the study’s Principal Investigators.
  • Additionally, the program will feature a discussion of real-world usage of CytoSorb®, that uses an equivalent polymer technology to DrugSorb-ATR and is already approved for this application in the European Union.
  • Click here for more details and to register.

Doing Digital Awards Honored Digital Pioneers: Brett King, Chris Skinner, Dirk Ohlmeier and Others

Retrieved on: 
Wednesday, April 17, 2024
Public sector, AI, Fintech, SPRING, Digital, ISAA, DDA, Bank, Central bank, Digital platform, DDF, Award, Cryptocurrency

YEREVAN, Armenia, April 17, 2024 (GLOBE NEWSWIRE) -- The Doing Digital Awards (DDA) was launched as a key side-event of SPRING PR's annual Doing Digital Forum.

Key Points: 
  • YEREVAN, Armenia, April 17, 2024 (GLOBE NEWSWIRE) -- The Doing Digital Awards (DDA) was launched as a key side-event of SPRING PR's annual Doing Digital Forum.
  • "Doing Digital Forum has evolved into a groundbreaking tradition where we gather with fellow change-makers, and thought leaders keen to exchange knowledge and expertise, propelling innovation forward.
  • Celebrating excellence in digitalization, the Doing Digital Awards have recognized pioneers like Brett King, Chris Skinner and Dirk Ohlmeier for their transformative impact on banking, fintech and talent growth.
  • "I hope that 'Doing Digital Awards' will become one of the best recognitions in the field.

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

Retrieved on: 
Friday, April 12, 2024
American Academy, Patient, AAN, Epilepsy, EEG, Therapy, Session 9, Ageing, Pharmaceutical industry

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.

Key Points: 
  • WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.
  • “This study underscores our ongoing dedication to enhancing the well-being of individuals battling epilepsy,” said Dan Barber, Aquestive President and Chief Executive Officer.
  • “When it comes to the treatment of seizure clusters in pediatric patients with epilepsy between ages two to five, we believe Libervant, as an oral alternative to existing device-based products, will be well-received by this patient population.”
    Poster Session 9: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Mechanisms, Pharmacokinetics, and Urgent Applications
    Presentation Time: Wednesday, April 17, from 8:00 AM - 9:00 AM.

AM Best Affirms Credit Ratings of Jacana Re Limited

Retrieved on: 
Wednesday, May 1, 2024
Insurance, Professional Services, News, Book, Credit, AM Best, Risk management, BHL, ALL, Reinsurance

AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a” (Excellent) of Jacana Re Limited (Jacana Re) (Guernsey).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a” (Excellent) of Jacana Re Limited (Jacana Re) (Guernsey).
  • The ratings reflect Jacana Re’s balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, limited business profile and appropriate enterprise risk management.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

AM Best Revises Outlooks to Positive for One Alliance Insurance Corporation

Retrieved on: 
Wednesday, May 1, 2024
Professional Services, Insurance, Finance, News, Credit, AM Best, ALL, Growth, FSR

The positive outlooks reflect the improvement in the company’s operating performance metrics over the past five years.

Key Points: 
  • The positive outlooks reflect the improvement in the company’s operating performance metrics over the past five years.
  • Management has been able to execute on its strategy, despite being a relatively new company in a mature and highly competitive market.
  • AM Best expects continued favorable trends over the near to intermediate term, which could result in a rating upgrade.
  • AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry.

Best’s Market Segment Report: U.S. Medical Professional Liability Segment’s Profitability Buoyed by Net Investment Income

Retrieved on: 
Wednesday, May 1, 2024
Insurance, Professional Services, MPL, AM Best, EDT, ALL, News, Growth

Premium growth for AM Best’s medical professional liability (MPL) composite moderated to 3.6% in 2023, but overall financial results were buoyed by favorable net investment income, according to a new AM Best report.

Key Points: 
  • Premium growth for AM Best’s medical professional liability (MPL) composite moderated to 3.6% in 2023, but overall financial results were buoyed by favorable net investment income, according to a new AM Best report.
  • The premium growth was spurred by price firming following a prolonged period of soft market conditions and challenging industry dynamics that dampened demand.
  • The new Best’s Market Segment Report on the U.S. MPL segment noted that improved underwriting results stalled last year, driven in part by rising loss adjustment and other underwriting expenses.
  • A panel of AM Best analysts and leading market executives will discuss the MPL segment in a complimentary market briefing scheduled for Wednesday, May 1, 2024, at 11:00 a.m. (EDT).

AM Best Affirms Credit Ratings of Pinnacle Life Limited

Retrieved on: 
Wednesday, May 1, 2024
Insurance, Professional Services, News, Credit, AM Best, Communication, Risk management, ERM, Good, ALL, Growth

AM Best has affirmed the Financial Strength Rating of B+ (Good) and the Long-Term Issuer Credit Rating of “bbb-” (Good) of Pinnacle life Limited (Pinnacle Life) (New Zealand).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of B+ (Good) and the Long-Term Issuer Credit Rating of “bbb-” (Good) of Pinnacle life Limited (Pinnacle Life) (New Zealand).
  • The ratings reflect Pinnacle Life’s balance sheet strength, which AM Best assesses as adequate, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management (ERM).
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

AM Best Affirms Credit Ratings of United Kingdom Mutual War Risks Association Limited

Retrieved on: 
Wednesday, May 1, 2024
Insurance, Professional Services, Investment, News, Risk, Credit, AM Best, Risk management, ALL

AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of United Kingdom Mutual War Risks Association Limited (UK War Risks or the Association) (United Kingdom).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of United Kingdom Mutual War Risks Association Limited (UK War Risks or the Association) (United Kingdom).
  • The ratings reflect UK War Risks’ balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

AM Best Upgrades Credit Ratings of Hamilton Re, Ltd. and Hamilton Insurance Designated Activity Company

Retrieved on: 
Tuesday, April 30, 2024
Insurance, Professional Services, Risk management, News, LP, Credit, AM Best, History, ALL, Reinsurance

AM Best has upgraded the Financial Strength Rating to A (Excellent) from A- (Excellent) and the Long-Term Issuer Credit Ratings to “a” (Excellent) from “a-” (Excellent) of Hamilton Re, Ltd. (Hamilton Re) (Pembroke, Bermuda) and Hamilton Insurance Designated Activity Company (Dublin, Ireland), each a wholly owned subsidiary of Hamilton Insurance Group, Ltd. (Pembroke, Bermuda) (collectively referred to as Hamilton).

Key Points: 
  • AM Best has upgraded the Financial Strength Rating to A (Excellent) from A- (Excellent) and the Long-Term Issuer Credit Ratings to “a” (Excellent) from “a-” (Excellent) of Hamilton Re, Ltd. (Hamilton Re) (Pembroke, Bermuda) and Hamilton Insurance Designated Activity Company (Dublin, Ireland), each a wholly owned subsidiary of Hamilton Insurance Group, Ltd. (Pembroke, Bermuda) (collectively referred to as Hamilton).
  • The outlook of these Credit Ratings (ratings) has been revised to stable from positive.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .